An adjuvanted H5N8 bird-flu vaccine built an immune response in a phase 2 trial
Two doses of an MF59-adjuvanted, cell-based H5N8 vaccine raised antibodies in most of 239 adults, including those over 65. It is a pandemic-preparedness candidate, not evidence that it prevents disease.
An experimental vaccine against H5N8 avian influenza produced an antibody response in most adults who received two doses, including people aged 65 and older, according to a phase 2 trial published on 7 November in Vaccine [s1]. The result is a step in pandemic preparedness — building and testing a vaccine against a strain that worries public-health agencies — not evidence that the shot prevents illness in the real world.
The backdrop is the steady spillover of H5 bird-flu viruses from animals to people. Clade 2.3.4.4b H5 viruses have spread widely in wild birds, poultry and, more recently, dairy cattle, and sporadic human infections have raised the risk of a strain that could spread between people. Having a vaccine designed, manufactured and tested in advance is the core logic of pandemic preparedness: the work is done before it is urgently needed, so it does not have to start from zero in a crisis.
What the trial did
The study was a phase 2, randomised, observer-blind, multi-centre trial of an MF59-adjuvanted, cell-based H5N8 vaccine built around the A/Astrakhan/3212/2020 clade 2.3.4.4b strain [s1]. Two features are worth unpacking. "Cell-based" means the vaccine antigen is grown in cultured cells rather than in chicken eggs — faster to scale and not dependent on egg supply, which matters when the pathogen itself threatens poultry flocks. "MF59-adjuvanted" means it includes an adjuvant, an ingredient that amplifies the immune response so each dose can use less antigen; dose-sparing is central to making enough vaccine quickly in a pandemic.
The trial enrolled 239 adults, split roughly evenly into an 18-to-64 cohort (121 people, including a subset of poultry workers) and a 65-and-older cohort (118 people) [s1]. Everyone received two priming doses. Antibody responses against H5N8 were measured by two laboratory assays — hemagglutination inhibition (HI) and microneutralization (MN) — on days 1, 22 and 43. Solicited side effects were tracked for seven days after each dose, and other adverse events through day 43 [s1].
What it found
Three weeks after the second dose, on day 43, the vaccine had raised antibody levels in both age groups [s1]. By HI, seroconversion — a defined jump in antibody titre — reached 75.8% (95% CI 66.1 to 83.8) in the 18-to-64 cohort and 71.0% (95% CI 61.1 to 79.6) in the 65-and-older cohort [s1]. A protective-threshold titre of at least 1:40 was achieved in 75.8% and 73.0% of the two groups, respectively.
The microneutralization assay told a consistent story, with seroconversion of 80.6% in the younger cohort and 70.0% in the older one, and titres of at least 1:40 in roughly 84% and 87% [s1]. The geometric mean fold increase in antibody — a measure of how much titres rose from baseline — was 13.7 in the younger group and 10.2 in the older group [s1]. Immune responses did not differ notably by whether participants were poultry workers.
On safety, most solicited side effects were mild or moderate and resolved within three days; unsolicited adverse events were reported by 16.7% of participants by day 43 [s1].
How to read it
This is an immunogenicity study, and that word sets the ceiling on what it shows. The trial measured antibodies in the blood, not whether vaccinated people avoid H5 infection or disease. Antibody titres such as a 1:40 HI level are long-standing regulatory benchmarks for seasonal flu vaccines, used as a stand-in for protection — but they are a proxy, and the correlation is less well established for a novel pandemic strain than for familiar seasonal ones.
The responses were also solid rather than near-universal: roughly a quarter of participants did not seroconvert by HI, and the older cohort, as is common with flu vaccines, responded somewhat less strongly than the younger one. The encouraging finding is that an adjuvanted two-dose schedule generated a response even in adults over 65, a group in which influenza vaccines often underperform.
What to watch
The value of a trial like this is that it adds a tested, scalable candidate to the shelf before a pandemic forces the question. The open items are the ones immunogenicity data cannot resolve: how durable the response is, how well it holds up against drifted H5 strains, and — the question only real-world use or a challenge could answer — whether the antibody response translates into protection. For context, see our coverage of H5 avian influenza and of pandemic vaccine preparedness.
This article describes an early-stage vaccine trial. It is not medical advice.
Sources
More on
How worried should people be about H5N1 bird flu? What the risk assessment says
The honest position is two things at once: the current risk to the general public is low, and the reason it is watched so closely is that its worst-case potential is high. The gap between the two is the whole story.
Risk nudges raised flu shots in three large US trials, AI disclosure aside
In preregistered trials of more than 90,000 patients, telling people an algorithm flagged them as high-risk lifted vaccination by a few points — and saying the algorithm was involved changed nothing.
Can you get flu and COVID shots at the same time? What the trials show
Two randomised UK trials tested giving the vaccines together. Systemic reactions stayed mostly mild and immune responses held up, though one trial saw more sore arms and a dip in COVID antibodies with co-administration.
Baloxavir cut influenza transmission in a trial, but not symptomatic cases
The CENTERSTONE trial found a single dose lowered lab-confirmed spread to household contacts by about a third, but spread that made contacts ill was not significantly cut, and resistant virus emerged in some patients.